3401 Technology Dr.
75 articles with Astellas Pharma
Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that it has successfully completed the first module of its previously announced research and option agreement with Astellas Pharma Inc
Astellas Pharma and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Inc. and Pfizer Inc. today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI®
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it exercised, and closed on its exclusive option to acquire Potenza Therapeutics, Inc. ("Potenza") on December 13, 2018, U.S. Eastern Time.
Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Astellas Pharma Inc. today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.1
Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced updated results from a Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients newly diagnosed with FLT3 mutation-positive (FLT3mut+) Acute Myeloid Leukemia (AML).
XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
FLT3 mutation-positive AML is a life-threatening disease with significant unmet medical needs
Foundation to Support Improving Access to Health for Underserved Populations
Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting
Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML
Cytokinetics, Incorporated and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions.
Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium
Anaeropharma Science Inc. announced on September 25 that Anaeropharma and Astellas Pharma Inc. have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, in situ Delivery and Production System ("i-DPS").
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anaemia not on Dialysis
Astellas Pharma Inc. today announced that roxadustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase activity, met its primary endpoints in the Phase 3 ALPS study
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.
Astellas Pharma Inc. and Ironwood Pharmaceuticals, Inc. announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist “Linzess® Tablets 0.25 mg
Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma
Four months after filing a supplemental New Drug Application with the U.S. Food and Drug Administration, Astellas and Pfizer snagged regulatory approval for Xtandi as a treatment for non-metastatic Castration-Resistant Prostate Cancer (CRPC).
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.